Synergistic anti-biofilm activity of

exebacase and rifampin, vancomycin or daptomycin

against Staphylococcus epidermidis strains

responsible for bone and joint infections

Aubin Souche, Camille Kolenda, Raymond Schuch, Tristan Ferry,

Frédéric Laurent, Jérôme Josse

CIRI - Centre International de Recherche en Infectiologie

Equipe Pathogénie des Staphylocoques

INSERM U1111 - CNRS UMR5308 - ENS Lyon - Université de Lyon

Conflict of interest

1

  • This study was founded by ContraFect Corporation
  • ContraFect Corporation have no impact on study design, results and interpretation

BJI epidemiolgy

2

Bone and Joint Infections

M & M

Bactericidal synergies ?

Anti-biomass synergies ?

Conclusion

  • Prevalence 70/100 000 inhbts
  • Morbidity 40% - Mortality 5%
  • Increasing number

BJI

Laurent et al. 2018

BJI epidemiolgy

2

Bone and Joint Infections

M & M

Bactericidal synergies ?

Anti-biomass synergies ?

Conclusion

  • Prevalence 70/100 000 inhbts
  • Morbidity 40% - Mortality 5%
  • Increasing number

BJI

S. aureus

>

30-70%

S. epidermidis

17-48%

Laurent et al. 2018

BJI epidemiolgy

2

Bone and Joint Infections

M & M

Bactericidal synergies ?

Anti-biomass synergies ?

Conclusion

  • Prevalence 70/100 000 inhbts
  • Morbidity 40% - Mortality 5%
  • Increasing number

BJI

S. aureus

>

30% = PJIff

S. epidermidis

Laurent et al. 2018

This is an excerpt of the original content. To continue reading it, access the original document here.

Attachments

  • Original document
  • Permalink

Disclaimer

ContraFect Corporation published this content on 19 July 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 19 July 2021 15:03:07 UTC.